# A Safety Study of SGN-CD33A in Combination With Standard-of-care in Patients With AML

> **NCT02326584** · PHASE1 · COMPLETED · sponsor: **Seagen Inc.** · enrollment: 116 (actual)

## Conditions studied

- Acute Myeloid Leukemia
- Acute Myelogenous Leukemia

## Interventions

- **DRUG:** Standard dose cytarabine for induction
- **DRUG:** SGN-CD33A
- **DRUG:** Daunorubicin
- **DRUG:** High dose cytarabine for consolidation

## Key facts

- **NCT ID:** NCT02326584
- **Lead sponsor:** Seagen Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-12
- **Primary completion:** 2017-01-30
- **Final completion:** 2018-04-10
- **Target enrollment:** 116 (ACTUAL)
- **Last updated:** 2018-05-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02326584

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02326584, "A Safety Study of SGN-CD33A in Combination With Standard-of-care in Patients With AML". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT02326584. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*